The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Open accessAbstract
Background & Aims Although anti–tumor necrosis factor (TNF) therapy can effectively treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's lymphoma (NHL). A meta-analysis was performed to determine the rate of NHL in adult CD patients who have received anti-TNF therapy and to compare this rate with that of a population-based registry and a population of CD patients treated with immunomodulators. Methods MEDLINE, EMBASE, Cochrane Collaboration, and Web of Science were searched. Inclusion criteria included randomized controlled trials, cohort studies, or case series reporting on anti-TNF therapy in adult CD patients. Standardized incidence ratios (SIR) were calculated by comparing the pooled rate of NHL with the expected rate of NHL derived from the Surveillance Epidemiology & End Results (SEER) database and a meta-analysis of CD patients treated with immunomodulators. Results Twenty-six studies involving 8905 patients and 21,178 patient-years of follow-up were included. Among anti-TNF treated subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years). The majority of these patients had previous immuno-modulator exposure. Compared with the expected rate of NHL in the SEER database (1.9 per 10,000 patient-years), anti-TNF treated subjects had a significantly elevated risk (SIR, 3.23; 95% confidence interval, 1.5–6.9). When compared with the NHL rate in CD patients treated with immunomodulators alone (4 per 10,000 patient-years), the SIR was 1.7 (95% confidence interval, 0.5–7.1). Conclusions The use of anti-TNF agents with immunomodulators is associated with an increased risk of NHL in adult CD patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Computed Tomography — An Increasing Source of Radiation Exposure
Brenner, D. J., & Hall, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra072149 · Cited by 8,748
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationCancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Kappelman, M. D., Rifas–Shiman, S. L., Kleinman, K., Ollendorf, D., Bousvaros, A., Grand, R. J., & Finkelstein, J. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.07.012 · Cited by 932
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D. (2005) · Gut · doi:10.1136/gut.2004.049460 · Cited by 808
Lichtenstein, G. R., Yan, S., Bala, M., Blank, M., & Sands, B. E. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.048 · Cited by 597
Self-citationPeyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
LÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Sands, B. E., Blank, M. A., Patel, K., & Van Deventer, S. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00414-8 · Cited by 359
Self-citationLjung, T., Karlén, P., Schmidt, D., Hellström, P. M., Lapidus, A., Janczewska, I., Sjöqvist, U., & Löfberg, R. (2004) · Gut · doi:10.1136/gut.2003.018515 · Cited by 313
120 Crohn's Disease: Factors Associated with Exposure to High Levels of Diagnostic Radiation
Desmond, A. N., O'Regan, K. N., Curran, C., McWilliams, S., Maher, M. M., & Shanahan, F. (2008) · Gastroenterology · doi:10.1016/s0016-5085(08)60102-x · Cited by 307
Inflammatory bowel disease is not associated with an increased risk of lymphoma
Lewis, J. D., Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J., & Strom, B. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.28703 · Cited by 296
Inflammatory Bowel Disease Is Not Associated With An Increased Risk Of Lymphoma
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200112000-00025 · Cited by 250
Peloquin, J. M., Pardi, D. S., Sandborn, W. J., Fletcher, J. G., McCollough, C. H., Schueler, B. A., Kofler, J. A., Enders, F. T. B., Achenbach, S. J., & Loftus, Jr. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01920.x · Cited by 199
Johnson, F. R., Özdemir, S., Mansfield, C., Hass, S., Miller, D. W., Siegel, C. A., & Sands, B. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.075 · Cited by 186
Self-citationRisk of lymphoma in inflammatory bowel disease
Loftus, E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01108-4 · Cited by 173
Fistulating Anal Crohn's Disease: Results of Combined Surgical and Infliximab Treatment
Hyder, S. A., Travis, S. P. L., Jewell, D. P., McC. Mortensen, N. J., & George, B. D. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0656-5 · Cited by 171
Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study
Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., et al. (2005) · Gut · doi:10.1136/gut.2005.075937 · Cited by 143
Perianal Fistulae Following Infliximab Treatment
Ardizzone, S., Maconi, G., Colombo, E. M., Manzionna, G., Bollani, S., & Porro, G. B. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200403000-00005 · Cited by 114
Infliximab in the surgical management of complex fistulating anal Crohn's disease
Talbot, C., Sagar, P. M., Johnston, M. J., Finan, P. J., & Burke, D. (2005) · Colorectal Disease · doi:10.1111/j.1463-1318.2004.00749.x · Cited by 95
Peyrin‐Biroulet, L., Laclotte, C., & Bigard, M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03254.x · Cited by 67
der, O. S., Blumenstein, I., & Stein, J. M. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200601000-00003 · Cited by 59
Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients
Seiderer, J., Göke, B., & Ochsenkühn, T. (2004) · Digestion · doi:10.1159/000080075 · Cited by 58
Kinney, T. P., Rawlins, M., Kozarek, R. A., France, R., & Patterson, D. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07286.x · Cited by 50
Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?
Johnson, F. R., Özdemir, S., Mansfield, C. A., Hass, S., Siegel, C. A., & Sands, B. E. (2008) · Risk Analysis · doi:10.1111/j.1539-6924.2008.01135.x · Cited by 48
Self-citationRetreatment and maintenance therapy with infliximab in fistulizing Crohn' disease
Rodrigo, L., Pérez-Pariente, J. M., Fuentes, D., Cadahía, V., García-Carbonero, A., Niño, P., de Francisco, R., Tojo, R., Moreno, M., & González-Ballina, E. (2004) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082004000800004 · Cited by 8
Cited by
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,106
Metadata
- Authors
- Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J., & Sands, B. E.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 7
- Issue
- 8
- Pages
- 874-881
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2105532585
- Cited by
- 511
- References
- 33
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.